Reprocell Japan

What Reprocell Japan does

Reprocell Japan (株式会社リプロセル) is a JASDAQ Growth-listed (code 4978) iPS cell technology platform company founded in February 2003 as a Kyoto University / University of Tokyo spin-out. The company's core technology is the StemRNA 3rd Gen RNA reprogramming kit, which generates iPS cells with minimized genomic damage by combining synthetic RNA with an MDM4/p53 suppression factor. It sells clinical-grade iPS cell seed clones manufactured to FDA, EMA, and PMDA standards, along with iPS-derived differentiated products (ReproCardio cardiomyocytes, ReproNeuro neuronal cells, ReproHepato hepatocytes, iPS neural glial cells for ALS) and an iPS exosome product line. It also develops regenerative medicine candidates including Stemchymal for spinal cerebellar degeneration (in partnership with Steminent Biotherapeutics), TIL therapy for solid tumors (Keio University), and Glypican-1 CAR-T therapy.

The company operates four go-to-market motions: (1) scientific direct sales plus field sales to academic researchers and pharmaceutical companies, (2) e-commerce via its own storefront, Amazon, and Rakuten for SMBs and consumers, (3) direct sales through wholly-owned subsidiaries in the USA (REPROCELL USA, Maryland), UK (REPROCELL Europe), and India (Bioserve), and (4) on-demand consumer services including COVID-19 PCR testing (8,800 yen/test, launched March 2021) and Well-Mil mail-in hormone and health testing kits (5,940-13,750 yen). Revenue is generated through one-time reagent and kit sales, recurring regenerative medicine and CDMO service contracts, and unit-priced diagnostic testing. Major customers include the National Cancer Center Japan, Kyoto University / CiRA, Keio University, Yokohama City University, and multiple pharmaceutical firms. Key strategic partners are BioBridge Global, CIRM, TEXCELL, Stemgent, Axion BioSystems, and Danaher; the company holds an exclusive RNA reprogramming license originating from the 2014 Stemgent acquisition and a registered patent on ES/iPS cell cryopreservation (ReproCryo RM).

Name

Reprocell Japan

Legal name

株式会社リプロセル

Website

https://reprocell.co.jp

Company type

Public

Founded year

2003

Operating status

Operating

Headcount range

1–10 employees

Short description

Reprocell Japan is a JASDAQ-listed (4978) iPS cell technology platform providing RNA reprogramming kits, clinical-grade iPS cell manufacturing, regenerative medicine products, and mail-in health testing kits to academic researchers, pharmaceutical firms, and consumers across Japan, the US, and Europe.

Ownership category

akta.pro rank

Product category

Regenerative Medicine and iPS Cell Technology Services

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)

akta.pro primary industry

Stem Cell Therapies (MSC/iPSC/HSC-derived) (HLAAABAE)

akta.pro secondary industries

Stem Cell–Based Regenerative Therapies (HLAAAGAA), Cell-Based & Potency Assays (Bioassays) (HLAGADAH)

Keywords

• IPS cell technology
• Regenerative medicine
• Stem cell research reagents
• Clinical cell manufacturing
• Cell therapy services

Headquarters

HQ city

Yokohama

HQ country

Japan

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales, Supply Chain

Revenue model

1. 研究支援サービス: 試薬・キット・培地・サービスの提供。iPS細胞関連製品群の研究支援
2. 再生医療&MEDI: 再生医療・細胞治療開発支援サービス
3. COVID-19 PCR検査: オンデマンドサービスとしてのPCR検査提供服务

Pricing tiers

Go-to-market motion2 records

Distribution channels7 records

Marketing channels7 records

Core offering

Reprocell Japan develops, manufactures, and sells iPS cell-based products and services for regenerative medicine and drug discovery. The core portfolio includes proprietary RNA reprogramming kits (StemRNA) for iPS cell generation, iPS-derived differentiated cell products (cardiomyocytes, neurons, hepatocytes) used in drug screening and toxicity testing, clinical-grade GMP-manufactured iPS cells, regenerative medicine candidates (Stemchymal, ALS neural glia, TIL and CAR-T therapies), iPS exosomes, Personal iPS individual cell banking, and the Well-Mil mail-in hormone/health testing service.

Product overview

Reprocell Japan operates as a comprehensive iPS cell technology platform company with research support and medical/life science business segments. The core product portfolio centers on StemRNA reprogramming technology for generating clinical-grade iPS cells, supplemented by iPS-derived products including exosomes (iPS exosome, bone marrow MSC exosome), cellular products (hepatocytes ReproHepato, cardiomyocytes ReproCardio, neural cells ReproNeuro including Alzheimer's models), and disease-specific therapies (Stemchymal for SCD, iPS neural glial cells for ALS, TIL therapy, CAR-T therapy). Supporting services include the Well-Mil mail-in testing kit, clinical HLA testing, COVID-19 PCR testing, and Personal iPS banking service. The company also distributes research equipment including Maestro MEA systems, Alvetex 3D culture tools, and Micronic sample storage solutions. GMP-compliant manufacturing facilities in Japan and the US support clinical-grade cell production for regenerative medicine applications.

Differentiator

Problem solved

Functional benefit

Brands

• Personal iPS: Personal iPS cell creation and storage service for individuals
• StemRNA
• Stemchymal
• ReproCardio
• ReproNeuro
• ReproHepato
• ReproCryo RM
• Well-Mil (ウェルミル)
• Alvetex
• Maestro Series
• iPS Exosome
• Femtech Tokyo

Products and services

• StemRNA - 3rd Gen Reprogramming Kit RNA-based reprogramming kit that uses synthetic mRNA to generate iPS cells from various cell sources (blood, fibroblasts, urine). Designed for researchers needing foot-print-free, genome-integrity-preserving iPS cell generation.
• StemRNA Clinical iPSC Seed Clones Clinical-grade iPS cells manufactured under FDA, EMA, and PMDA regulatory standards with master cell bank availability for regenerative medicine applications.
• iPS Exosome GMP-compliant iPS cell-derived exosomes purified and concentrated from iPS cell culture supernatant for anti-aging research with reported effects on collagen production and cell proliferation maintenance.
• Stemchymal Adipose-derived stem cell product targeting spinal cerebellar degeneration (SCD). In clinical trials with partner Steminent; positioned as a candidate for first regenerative medicine product approval.
• Well-Mil Mail-in Testing Service Mail-in testing service for hormone levels (estrogen, testosterone, cortisol, AMH, thyroid) and health checkups, offered as saliva and blood test kits to individual consumers.
• Clinical HLA Testing Service Clinical testing services including anti-HLA antibody screening and single antigen identification testing for organ transplant compatibility, covered by Japanese national health insurance.
• COVID-19 PCR Testing Service COVID-19 PCR testing service using SmartAmp method capable of detecting multiple mutant strains. Offered as on-demand testing for clinics and individuals with unit pricing of 8,800 yen per test (regular) and 5,800 yen tax-included (limited-time March 2021 price).
• Personal iPS Cell Creation and Storage Service Personal iPS cell creation and storage service for individual customers using teeth or urine samples, with iPS cells stored at dual Japan-US locations for disaster preparedness.
• iPS-derived Differentiated Cell Products (ReproCardio, ReproNeuro, ReproHepato) Human iPS cell-derived differentiated cell products including cardiomyocytes (ReproCardio), neuronal cells (ReproNeuro including dopaminergic/cholinergic neurons and Alzheimer's disease models), and hepatocytes (ReproHepato) for drug discovery, cardiac safety testing, neurological research, and toxicity evaluation.
• Micronic Sample Storage Solutions 2D barcode-coded tubes and automation equipment from Dutch company Micronic for sample storage and management in research laboratories.
• TIL Therapy (Tumor-Infiltrating Lymphocyte) Tumor-infiltrating lymphocyte therapy for cervical cancer and solid tumors, developed in partnership with Keio University as one of Reprocell's four key regenerative medicine pipeline assets.
• Glypican 1 CAR-T Therapy CAR-T cell therapy targeting Glypican 1 for solid tumor treatment, part of Reprocell's four key regenerative medicine pipeline assets.
• Maestro Multi-Electrode Array (MEA) Systems Multi-electrode array (MEA) systems for electrophysiology research and cancer studies, manufactured by Axion BioSystems and distributed by Reprocell.
• Alvetex 3D Cell Culture Platform 3D cell culture equipment and scaffolds for forming spheroids and 3D tissue models, originally developed by Reinnervate Ltd (UK) and recognized with CV Technology Innovator Awards 2016.

Quantifiable outcome

• ゲノム損傷リスクを最小化したiPS細胞作製

Named customers5 records

Segments3 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Eight partnerships are on record, tiered core and minor.

• BioBridge Global社coreStrategic or Co-development Partner · 31 March 2021臨床用iPS細胞の提供から治験薬製造までの一連の流れを確立する戦略的パートナーシップ。再生医療の臨床応用に向けた包括的協力関係
• californium CIRM（カリフォルニア州再生医療機構）coreStrategic or Co-development Partner · 31 March 2021臨床用iPS細胞事業での協力。California Institute for Regenerative Medicineとの臨床グレードiPS細胞開発パートナーシップ
• TEXCELL社coreStrategic or Co-development Partner · 31 March 2021GMP-iPS細胞マスターセルバンク製造販売における戦略的業務提携。GMP準拠製造の外部委託パートナー
• Histocell社（スペイン）minorStrategic or Co-development Partnerスペインのリムポール型企业との戦略的出资関係
• Stemgent社coreTechnology or IntegrationRNAリプログラミング技術（Stemgent社技術）の導入・活用によるiPS細胞作製効率の向上
• Axion BioSystems社coreTechnology or IntegrationMaestroシリーズの製造元。MEA（Multi-Electrode Array）製品での協業
• Cellco Labs社（スウェーデン）minorChannel Partner/ Reseller/ Distributorスウェーデンのパートナー企業。エクソーム製品の 유통 거점
• 横浜ビー・コルセアーズminorGTM or Marketing PartnerB.LEAGUE所属バスケットボールチームとのタイアップ。マーケティングパートナーシップ

Scale indicators3 records

Recent moves12 records

Expansion highlights7 records

Broad incumbents

• Lonza Group: Lonza is one of the world's largest cell and gene therapy CDMOs with extensive GMP manufacturing capacity for cell-based therapies. As Reprocell scales its clinical-grade iPS cell manufacturing in the new Maryland facility, it competes with Lonza's established CDMO network for regenerative medicine customers globally.
• Cytiva: Cytiva (formerly GE Healthcare Life Sciences) supplies bioprocessing equipment, single-use technologies, and cell therapy manufacturing solutions used by regenerative medicine developers. Its cell therapy workflow products are complementary to and competitive with aspects of Reprocell's cell processing infrastructure.
• Catalent: Catalent is a global CDMO with significant cell therapy manufacturing capacity acquired through the Paragon and MaSTHERCell platforms, competing for outsourced production of regenerative medicine products. Reprocell's new Maryland GMP facility and TEXCELL partnership target the same customer demand for clinical-grade cell manufacturing.
• Thermo Fisher Scientific (Gibco Cell Culture): Thermo Fisher Scientific through its Gibco brand is the dominant global supplier of cell culture media, reagents, and stem cell research products, including iPSC maintenance and differentiation media. Reprocell's ReproXF and related media products compete in the same life sciences research tools category.

Emerging players

• Ncardia: Ncardia is a European iPSC-focused company producing cardiac and neuronal cell products for drug discovery and toxicity testing, with industrial-scale manufacturing capabilities. It competes directly with Reprocell for pharmaceutical customers seeking iPSC-derived cardiac safety and neurotoxicity assays.
• Century Therapeutics: Century Therapeutics develops iPSC-derived allogeneic cell therapies (iNK and iT cell platforms) for oncology, positioning itself in the same iPSC-to-therapy value chain Reprocell aspires to capture with its Stemchymal and CAR-T programs. It represents a more narrowly-focused but well-funded emerging competitor in iPSC-derived therapeutics.
• Axol Bioscience: Axol Bioscience is a UK-based company that produces iPSC-derived human cells (neurons, cardiomyocytes, microglia) and contract assay services for drug discovery. It serves the same pharma/biotech customer segment with overlapping iPSC-derived cell product and assay offerings to Reprocell.

Direct peers

• Takara Bio: Takara Bio is a major Japanese biotech that acquired Cellartis and offers a competing iPSC-derived cell portfolio (including cardiomyocytes and hepatic cells) plus gene therapy tools and cell processing services. It is one of Reprocell's most direct Japanese competitors in both research reagents and regenerative medicine CDMO services.
• Fujifilm Cellular Dynamics: Fujifilm Cellular Dynamics is the largest commercial supplier of iPSC-derived cells (cardiomyocytes, neurons, hepatocytes, endothelial cells) for drug discovery and toxicity testing, directly competing with Reprocell's ReproCardio, ReproNeuro, and ReproHepato product lines. Both companies target pharmaceutical customers seeking human iPSC-based assays as alternatives to animal testing.
• Stemcell Technologies: Stemcell Technologies is a leading global supplier of stem cell research products (culture media, primary cells, differentiation kits) and operates contract research services. It competes with Reprocell's research reagent portfolio (ReproXF, ReproHSC, StemRNA) and shares the same academic and pharma research customer base.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/_REPROCELL
• Facebookfacebook.com/reprocelljapan
• LinkedInjp.linkedin.com/company/reprocell

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Subsidiaries4 records

Funding overview

Funding rounds5 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Reprocell Japan